Company / Operating Cash Flow per Share
RAPT Therapeutics, Inc. Operating Cash Flow per Share History
FY2018-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Cash Flow per Share
-$2.04
FY2024
5-year range
-$2.53 / -$1.68
FY2020-FY2024
Trend
+19.3%
vs FY2023
Sector context
#147 of 208
Health Care
What the data says
At $-2.04, RAPT Therapeutics, Inc.'s operating cash flow per share ranks #147 of 208 in the Health Care sector. Operating Cash Flow per Share has fluctuated over the past 7 years, ranging from $-52.95 in FY2018 to $-1.68 in FY2020.
Based on SEC 10-K filings.
-2.04 in FY2024.
Improved from $-2.17 to $-2.04 over the past 2 years.
Health Care sector context is included.
Operating Cash Flow per Share over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#147 of 208 in Health CareTop 71% of 208This company -$2.04 Sector average -$21.21
▼
+90.4% above sector average
Key checks
Key Insights
- In FY2024, operating cash flow per share increased 19.3% year-over-year.
- Ranks #147 out of 208 companies in the Health Care sector.
- Peak operating cash flow per share was recorded in FY2020.
- Lowest operating cash flow per share in the period was in FY2018.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 0.38 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating Cash Flow per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | -$2.04 | +19.3% |
| FY2023 | -$2.53 | -16.4% |
| FY2022 | -$2.17 | +2.4% |
| FY2021 | -$2.23 | -32.8% |
| FY2020 | -$1.68 | +79.4% |
| FY2019 | -$8.16 | +84.6% |
| FY2018 | -$52.95 | - |
As of FY2024 · SEC 10-K · Updated Feb 28, 2026